On October 10, 2024, the Food and Drug Administration authorized inavolisib (Itovebi, Genentech, Inc.) in conjunction with palbociclib and fulvestrant for adults diagnosed with endocrine-resistant, ...
her2-negative-breast-cancer
On September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in conjunction with an aromatase inhibitor for the adjuvant therapy of adult...
her2-negative-breast-cancer